<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02584075</url>
  </required_header>
  <id_info>
    <org_study_id>Exen100</org_study_id>
    <nct_id>NCT02584075</nct_id>
  </id_info>
  <brief_title>Evaluate the Effect of Exenatide Treatment on Coronary Artery Endothelial Function</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Chao Yang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Chao Yang Hospital</source>
  <brief_summary>
    <textblock>
      Type 2 diabetes mellitus (T2DM) is an important risk factor of cardio-cerebral vascular&#xD;
      disease such as coronary heart disease. GLP-1 is a kind of incretin secreted by the L-cell&#xD;
      located in Ileum. It acts as an incretin hormone by protentiating glucose-stimulated insulin&#xD;
      release. Recent studies reported that GLP-1 RA can protect the vascular endothelial and&#xD;
      prevent vascular from atherosclerosis. Investigators design this study to investigate&#xD;
      exenatide's effect on the improvement of the coronary endothelial function by evaluating&#xD;
      endothelium dependent diastolic function and testing the vascular endothelial active&#xD;
      substance and related inflammatory factors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Coronary endothelial function</measure>
    <time_frame>the change of coronary endothelial function(baseline, 12 weeks)</time_frame>
    <description>the change of coronary flow velocity reserve (CFVR)(baseline, 12 weeks)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the changes of fasting plasma glucose (FPG)</measure>
    <time_frame>the changes of fasting plasma glucose (FPG)(baseline, 12 weeks)</time_frame>
    <description>the changes of fasting plasma glucose (FPG) (baseline, 12 weeks)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the changes of HbA1C</measure>
    <time_frame>the changes of HbA1C(baseline, 12 weeks)</time_frame>
    <description>the changes of HbA1C (baseline, 12 weeks)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the changes of fasting serum insulin (FINS)</measure>
    <time_frame>the changes of fasting serum insulin (FINS) (baseline, 12 weeks)</time_frame>
    <description>the changes of fasting serum insulin (FINS) (baseline, 12 weeks)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the changes of IL-1B</measure>
    <time_frame>the changes of IL-1B (baseline, 12 weeks)</time_frame>
    <description>the changes of IL-1B (baseline, 12 weeks)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the changes of IL-6</measure>
    <time_frame>the changes of IL-6 (baseline, 12 weeks)</time_frame>
    <description>the changes of IL-6 (baseline, 12 weeks)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the changes of TNF-α</measure>
    <time_frame>the changes of TNF-α(baseline, 12 weeks)</time_frame>
    <description>the changes of TNF-α(baseline, 12 weeks)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Coronary Endothelial Function</condition>
  <arm_group>
    <arm_group_label>Lifestyle intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Byetta (Exenatide)</intervention_name>
    <description>Exenatide treatment: 5 µg twice/day subcutaneous injection for 4 weeks, 10 µg twice/day subcutaneous injection for 8 weeks.</description>
    <arm_group_label>Lifestyle intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucophage ( Metformin Hydrochloride)</intervention_name>
    <description>Metformin 500mg Tid</description>
    <arm_group_label>Lifestyle intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Females or males, and aged 20 to 65 years&#xD;
&#xD;
          -  Newly diagnose type 2 diabetes mellitus with BMI&gt;25kg/m2.&#xD;
&#xD;
          -  HbA1C&gt;8%.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 1 diabetes mellitus, diabetic ketoacidosis, diabetic hyperosmolar coma.&#xD;
&#xD;
          -  Hepatic insufficiency (ALT or AST&gt; 1.5*ULN).&#xD;
&#xD;
          -  Renal insufficiency [Creatinine clearance rate (Ccr)]&lt;60ml/min estimated from MDRD&#xD;
             equation).&#xD;
&#xD;
          -  Thyroid disease&#xD;
&#xD;
          -  Use of any anti-diabetic, anti-hypertension or anti-dyslipidemia drugs.&#xD;
&#xD;
          -  Pregnant or lactating woman.&#xD;
&#xD;
          -  Severe anemia.&#xD;
&#xD;
          -  Acute myocardial infarction or stoke.&#xD;
&#xD;
          -  Other conditions at investigator's discretion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>October 15, 2015</study_first_submitted>
  <study_first_submitted_qc>October 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2015</study_first_posted>
  <last_update_submitted>October 21, 2015</last_update_submitted>
  <last_update_submitted_qc>October 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Chao Yang Hospital</investigator_affiliation>
    <investigator_full_name>Guang Wang</investigator_full_name>
    <investigator_title>Director,Head of Endocrinology,Principal Investigator, Clinical Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

